-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMGN-151 in Epithelial Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMGN-151 in Epithelial Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMGN-151 in Epithelial Ovarian Cancer Drug Details: IMGN-151 is under development...
-
Product Insights
NewNet Present Value Model: ImmunoGen Inc’s Pivekimab sunirine
Empower your strategies with our Net Present Value Model: ImmunoGen Inc's Pivekimab sunirine report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMGN-151 in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMGN-151 in Endometrial Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMGN-151 in Endometrial Cancer Drug Details: IMGN-151 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Galinpepimut-S in Multiple Myeloma (Kahler Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Galinpepimut-S in Multiple Myeloma (Kahler Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Galinpepimut-S in Multiple Myeloma (Kahler Disease) Drug Details: Galinpepimut-S is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Enristomig in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Enristomig in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Enristomig in Adenocarcinoma Of The Gastroesophageal Junction Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mirvetuximab Soravtansine in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mirvetuximab Soravtansine in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mirvetuximab Soravtansine in Triple-Negative Breast Cancer (TNBC) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PVX-410 in Multiple Myeloma (Kahler Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PVX-410 in Multiple Myeloma (Kahler Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PVX-410 in Multiple Myeloma (Kahler Disease) Drug Details: PVX-410 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PVX-410 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PVX-410 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PVX-410 in Triple-Negative Breast Cancer (TNBC) Drug Details: PVX-410 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Galinpepimut-S in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Galinpepimut-S in Small-Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Galinpepimut-S in Small-Cell Lung Cancer Drug Details: Galinpepimut-S is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Galinpepimut-S in Fallopian Tube Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Galinpepimut-S in Fallopian Tube Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Galinpepimut-S in Fallopian Tube Cancer Drug Details: Galinpepimut-S is under...